Avimanyu Datta PhD Overview A coherent technological innovation strategy leverages the firms existing competitive position and provides direction for future development of the firm Formulating this strategy requires ID: 677076
Download Presentation The PPT/PDF document "Chapter 6 Defining the Organization's St..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Chapter 6
Defining the Organization's Strategic Direction
Avimanyu
Datta
, PhDSlide2
Overview
A coherent technological innovation strategy leverages the firm’s existing competitive position and provides direction for future development of the firm.
Formulating this strategy requires:
Appraising the firm’s environment,
Appraising the firm’s strengths, weaknesses, competitive advantages, and core competencies,
Articulating an ambitious strategic intent.Slide3
Assessing the Firm’s Current Position
External Analysis
Two common methods are Porter’s Five-Force Model and Stakeholder Analysis.
Porter’s Five-Force Model
Degree of existing rivalry
. Determined by number of firms, relative size, degree of differentiation between firms, demand conditions, exit barriers.
Threat of potential entrants
. Determined by attractiveness of industry, height of entry barriers (e.g., start-up costs, brand loyalty, regulation, etc.)
Bargaining power of suppliers
. Determined by number of suppliers and their degree of differentiation, the portion of a firm’s inputs obtained from a particular supplier, the portion of a supplier’s sales sold to a particular firm, switching costs, and potential for vertical integration. Slide4
Assessing the Firm’s Current Position
Bargaining power of buyers
. Determined by number of buyers, the firm’s degree of differentiation, the portion of a firm’s inputs sold to a particular buyer, the portion of a buyer’s purchases bought from a particular firm, switching costs, and potential for vertical integration.
Threat of substitutes.
Determined by number of potential substitutes, their closeness in function and relative price.
Recently Porter has acknowledged the
role of complements
. Must consider:
how important complements are in the industry,
whether complements are differentially available for the products of various rivals (impacting the attractiveness of their goods), and
who captures the value offered by the complements.
Slide5
Assessing the Firm’s Current Position
Five-Force ModelSlide6
Assessing the Firm’s Current Position
Stakeholder Analysis
Who are the stakeholders.
What does each stakeholder want.
What resources do they contribute to the organization.
What claims are they likely to make on the organization.Slide7
Assessing the Firm’s Current Position
Internal Analysis
Identify the firm’s strengths and weaknesses. Helpful to consider each element of value chain. Slide8
2. Assess which strengths have potential to be
sustainable competitive advantage
Rare
Valuable
Non-substitutable
Inimitable
Resources
are difficult (or impossible) to imitate when they are:
Tacit
Path dependent
Socially complex
Causally ambiguous
Assessing the Firm’s Current Position
Competitive Advantage
Sustainable
Competitive AdvantageSlide9
Identifying Core Competencies and Capabilities
Core Competencies
: A set of integrated and harmonized abilities that distinguish the firm in the marketplace.
Competencies typically combine multiple kinds of abilities.
Several core competencies may underlie a business unit.
Several business units may draw from same competency.
Core competencies should:
Be a significant source of competitive differentiation
Cover a range of businesses
Be hard for competitors to imitateSlide10
Identifying Core Competencies and CapabilitiesSlide11
Identifying the Firm’s Core Competencies
Gallon,
Stillman
and Coates offer a step-by-step program for identifying core competencies.
Module 1
-- Assemble a steering committee, appoint a program manager, and communicate the overall goals of the project to all members of the firm.
Module 2
-- Constructing an inventory of capabilities categorized by type. Assess their strength, importance, and criticality.
Module 3 –
Organize capabilities by both their criticality and the current level of expertise within the firm for each.
Module 4
– Distill competencies into possible candidates for the firm to focus on. No options should be thrown out yet.
Module 5
-- Testing the candidate core competencies against
Prahalad
and Hamel's original criteria.
Module 6
-- Evaluate the firm’s position in the core competency.
Research BriefSlide12
Risk of Core Rigidities
When firms excel at an activity, they can become over committed to it and rigid.
Incentives and culture may reward current competencies while thwarting development of new competencies.
Dynamic capabilities
are competencies that enable the firm to quickly respond to change.
E.g., firm may develop a set of abilities that enable it to rapidly deploy new product development teams for a new opportunity; firm may develop competency in working with alliance partners to gain needed resources quickly.Slide13
Strategic Intent
Strategic Intent
A long-term goal that is ambitious, builds upon and stretches firm’s core competencies, and draws from all levels of the organization.
Typically looks 10-20 years ahead, establishes clear milestones
Firm should identify resources and capabilities needed to close gap between strategic intent and current position. Slide14
The Balanced Scorecard
Kaplan and Norton argue
that effective performance
measurement should
incorporate:
Financial perspective
Customer perspective
Internal perspective
Innovation and learning
Theory In ActionSlide15
Genzyme was founded in 1981 by scientists studying genetically inherited enzyme diseases
Adopted a very unusual strategy of developing drugs for rare diseases rather than “blockbuster” drugs.
Smaller markets, but fewer competitors
Requires less advertising, smaller sales force
In 1983, the FDA established the “Orphan Drug Act,” giving seven years market exclusivity to developers of drugs for rare (<200,000 patients) diseases.
Also chose unusual strategy of doing its own manufacturing and sales rather than licensing to a pharmaceutical company.
Diversified into side businesses to fund its R&D.
By 2009, was one of the world’s largest biotech companies with 10,000 employees in 40 countries.
Genzyme’s Focus on
“Orphan Drugs”Slide16
Discussion Questions:
1. How does Genzyme’s focus on orphan drugs affect the degree of competition it faces? How does it affect the bargaining power of customers?
2. How does focusing on orphan drugs affect the types of resources and capabilities a biotech firm needs to be successful?
3. Does Genzyme’s focus on orphan drugs make sense? Do you think Genzyme has a long-term strategic intent?
4. Why do you think Genzyme has diversified into other areas of medicine? What are the advantages and disadvantages of this?
5. What recommendations would you offer Genzyme for the future?
Genzyme’s Focus on
“Orphan Drugs”Slide17
Discussion Questions
What is the difference between a
strength
, a
competitive advantage
, and a
sustainable competitive advantage
?
What makes an ability (or set of abilities) a
core competency
?
Why is it necessary to perform an external and internal analysis before the firm can identify its true core competencies?
Pick a company you are familiar with. Can you identify some of its core competencies?
How is the idea of “strategic intent” different from models of strategy that emphasize achieving a fit between the firm’s strategies and its current strengths, weaknesses, opportunities and threats (SWOT)?
Can a strategic intent be too ambitious?